RXII - RXIファ―マシュ―ティカルズ (RXi Pharmaceuticals Corporation) RXIファ―マシュ―ティカルズ

 RXIIのチャート


 RXIIの企業情報

symbol RXII
会社名 RXI Pharmaceuticals Corp (New) (RXIファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company''s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone a topical immunomodulator. Its clinical development programs include RXI-109 an sd-rxRNA for the treatment of dermal and ocular scarring and Samcyprone for the treatment of such disorders as warts alopecia areata non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas including dermatology ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence or down-regulate the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing enhancing or suppressing an immune response.   RXIファ―マシュ―ティカルズは米国のバイオ医薬品会社。RNA干渉(RNAi)プラットフォ―ムに基づく治療の発見と開発、商品化に注力する。開発中のRNAi化合物には、「rxRNAori」と「sd-rxRNA」がある。また、臨床段階の主要な製品候補「RXI-109」は、皮膚瘢痕の予防や減少のために開発された「sd-rxRNA」である。   RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.
本社所在地 257 Simarano Drive Suite 101 Marlborough MA 01752 USA
代表者氏名 Robert J. Bitterman ロバートJ.ビッターマン
代表者役職名 Independence Chairman of the Board
電話番号 +1 508-767-3861
設立年月日 40787
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.rxipharma.com
nasdaq_url https://www.nasdaq.com/symbol/rxii
adr_tso
EBITDA EBITDA(百万ドル) -8.52100
終値(lastsale) 0.5687
時価総額(marketcap) 2502280
時価総額 時価総額(百万ドル) 1.92558
売上高 売上高(百万ドル) 0.09600
企業価値(EV) 企業価値(EV)(百万ドル) -3.38942
当期純利益 当期純利益(百万ドル) -8.61800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 RXi Pharmaceuticals Corp revenues increased from $0K to $81K. Net loss decreased 48% to $4.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Acquired in-process research and develop decrease from $4.7M (expense) to $0K General and administrative expenses - Ba decrease of 22% to $1.6M (expense).

 RXIIのテクニカル分析


 RXIIのニュース

   RXI Pharmaceuticals Corporation (RXII) CEO Dr. Geert Cauwenbergh on Q3 2018 Results - Earnings Call Transcript  2018-11-14
RXI Pharmaceuticals Corporation (RXII) Q3 2018 Earnings Conference Call November 14, 2018 04:30 PM ET Executives Caitlin Kontulis - Senior Director of Finance Dr. Geert Cauwenbergh - CEO Dr. Gerrit Dispersyn - President and COO Analysts Anita Dushyanth - Zacks Small Capital…
   RXi Pharmaceuticals beats by $0.17, beats on revenue  2018-11-14
RXi Pharmaceuticals (NASDAQ: RXII ): Q3 GAAP EPS of -$0.34 beats by $0.17 . More news on: RXI Pharmaceuticals Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more …
   RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights  2018-11-14 PR Newswire
MARLBOROUGH, Mass. , Nov. 14, 2018 /PRNewswire/ --RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, reports its f…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 RXIファ―マシュ―ティカルズ RXII RXi Pharmaceuticals Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)